| Accession |
PRJCA018959 |
| Title |
A Three-Arm, Randomised, Double-Blind, Multicentre, Phase III Clinical Study in First-Line Treatment of NSCLC |
| Relevance |
Medical |
| Data types |
Genetic mutation result and biomarker
|
| Organisms |
Homo sapiens
|
| Description |
HLX10-002-NSCLC301:A Three-Arm, Randomised, Double-Blind, Multicentre, Phase III Clinical Study to Evaluate HLX10 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Pemetrexed) Versus HLX10 + HLX04 (Recombinant Anti-VEGF Humanised Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Pemetrexed) Versus Chemotherapy (Carboplatin-Pemetrexed) as First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of HLX10 combined chemotherapy and HLX10+HLX04 combined chemotherapy versus chemotherapy in subjects who had not previously received systemic treatment for advanced non-squamous NSCLC, collect PK parameters, and explore biomarkers related to efficacy. |
| Sample scope |
Multiisolate |
| Release date |
2023-08-13 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Yuankai
Shi (syuankaipumc@126.com)
|
| Organization |
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission date |
2023-08-10 |
